The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen.
10.19746/j.cnki.issn.1009-2137.2021.06.018
- Author:
Bing-Jie FAN
1
;
Huan CHEN
1
;
Chen-Xing SHANGGUAN
1
;
Xi-Yang LIU
1
;
Yu CHANG
1
;
Lei ZHANG
2
Author Information
1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
2. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China,E-mail: zl2909@163.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide;
Doxorubicin;
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Middle Aged;
Prednisolone;
Prognosis;
Vincristine/therapeutic use*;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(6):1797-1801
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the treatment outcome and prognosis of the newly-treated myc
METHODS:152 double-expression lymphoma patients (myc
RESULTS:The median age of 152 DEL patients was 60.5 years old (15-87 years old). 85 patients (55.9%) were Ann Arbor stage III/IV. There was no significant difference in clinical data between the patients in the two groups. Multivariate Cox regression analysis showed that bcl-6 expression, ECOG score, and stage were the independent prognostic factors for the entire group of DEL patients. There was no statistical difference in ORR between the patients in the two groups (χ2=0.749, P=0.387). Kaplan-Meier survival analysis showed that PFS and OS of the bcl-6
CONCLUSION:bcl-6
